Thymosin Alpha-1 is a 28-amino-acid thymic peptide that tunes the immune system — not muscle.

The short version

Thymosin Alpha-1 is a tiny protein your body already makes. It is a 28-amino-acid peptide (a short chain of protein building blocks) that the thymus — a small gland behind the breastbone that schools the immune system — helps produce. Its job is not to build muscle or burn fat. It is an immune modulator: it nudges immune cells to work better when defenses are weak and helps calm them when they overreact. In labs and clinics it has been studied mostly as an injection for chronic viral hepatitis, sepsis, severe COVID-19, and as an add-on in cancer care. The synthetic, lab-made version is called thymalfasin. The honest state of the evidence is mixed: it looks helpful in some settings and made no difference in the single biggest, most careful sepsis trial. It is not approved for sale in the United States. What people report — including the downsides, and who should be careful — is on the effects page.

What the literature has established

Goldstein and colleagues isolated Thymosin Alpha-1 from calf thymus and, in 1977, determined its complete 28-residue, acetylated sequence — the founding paper of the entire field ^[1]. The molecule that emerged is highly acidic, carries no aromatic residues and no disulfide bonds, and is cleaved inside the body from a larger precursor called prothymosin alpha. The acetyl cap on its front end is not decorative; it is required for activity.

Mechanistically, Thymosin Alpha-1 sits at the seam between innate and adaptive immunity — the fast, general first line of defense and the slower, specific one. It signals through pattern-recognition receptors called Toll-like receptors (TLR2 and TLR9) on dendritic cells (the immune system's scouts, which show captured fragments to other cells) and monocytes, pushing them to mature, make interleukin-12, and present antigen more effectively ^[5]. That, in turn, drives T-cell maturation and a Th1 (cell-mediated) immune slant. In parallel the peptide engages the IDO pathway — an enzyme route that quiets immunity — to generate regulatory T cells, giving it an unusual dual character: restore effector immunity where it has collapsed, dampen it where it has run wild ^[5].

That dual character is the thread running through everything the compound has been studied for. A peptide that can both lift and restrain immunity is, on paper, a candidate for two opposite problems — a worn-down immune system that cannot clear a chronic virus, and an inflamed one that is damaging its own host. The literature has tested both ideas, and the most convincing results landed on the first.

Where the trials landed

The clinical record is real, large, and uneven. In the multicentre ETASS trial of 361 patients with severe sepsis, 28-day all-cause mortality was 26.0% with Thymosin Alpha-1 versus 35.0% in controls — about a 9-point absolute reduction that fell just short of conventional significance ^[2]. That promising signal was then tested at scale. The phase-3 TESTS trial enrolled 1,106 adults with sepsis across 22 centres and found no significant difference in 28-day mortality (23.4% vs 24.1%; hazard ratio 0.99, 95% CI 0.77-1.27, P=0.93) ^[3]. The largest and most rigorous sepsis study to date was null, and it tempers the earlier, lower-quality positive results.

The evidence is steadier elsewhere. A comprehensive four-decade review reports the peptide is approved abroad in more than 35 countries, is generally well tolerated, and carries a benign safety profile dominated by mild injection-site reactions ^[4]. In chronic hepatitis B, combining the peptide with antiviral therapy raised hepatitis B e-antigen seroconversion to 45.1% versus 15.2% for antiviral alone across eight trials ^[9]. You can read the Thymosin Alpha-1 research in full, see how it signals on the thymosin alpha 1 mechanism of action page, or start with the basics on the thymosin alpha 1 peptide page.

A peptide that is constantly confused

Part of reading this literature accurately is keeping Thymosin Alpha-1 distinct from the molecules it shares a name-family with. It is not thymosin beta-4 — the 43-amino-acid actin-binding peptide that gives rise to the fragment marketed as TB-500, and the one that sits in the WADA-prohibited category. It is not thymulin (a zinc-dependent nonapeptide), not thymopentin (a pentapeptide), and not thymalin (a separate bovine thymic-extract preparation). And it is not prothymosin alpha, the larger precursor it is cut from. These are different molecules with different sequences, sizes, and jobs — on a gel they would resolve as separate bands at separate weights. The peptide is also not anabolic: there is no evidence it builds muscle, and framing it as a performance compound misreads what it does. It is an immune-tuning peptide, full stop.

What this site is

This is an editorial digest. It summarizes the peer-reviewed literature on Thymosin Alpha-1 and keeps the caveats in view: the often China-centred trial base, the mixed COVID-19 data, and the absence of US marketing approval. It does not sell anything, does not recommend a dose, and does not give medical advice. Every quantitative claim on the site maps to a numbered citation in the Thymosin Alpha-1 references. The full mechanism, study by study, is on the Thymosin Alpha-1 research page; reported benefits, side effects, and cautions are gathered on the Thymosin Alpha-1 effects page; and the doses that actually appear in the trials — reported only as study parameters, never as advice — are on the dosage page.